Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation

JIE Guang-ling; NIU Xiao-min

doi:10.12019/j.issn.1671-5144.202402008

JIE Guang-ling, NIU Xiao-min. Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008

Citation:

JIE Guang-ling, NIU Xiao-min. Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008

Citation:

JIE Guang-ling, NIU Xiao-min. Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008

Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation

Graphical Abstract

Abstract

FullText(HTML)

References (30)

Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation

Catalog

Export File

Citation

Format

Content